BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37752440)

  • 21. Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo.
    Ranathunga I; Athukorala TG; Sumanatilleke MR; Somasundaram NP
    BMC Endocr Disord; 2022 Nov; 22(1):289. PubMed ID: 36411444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
    Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
    J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.
    Kumarendran B; O'Reilly MW; Manolopoulos KN; Toulis KA; Gokhale KM; Sitch AJ; Wijeyaratne CN; Coomarasamy A; Arlt W; Nirantharakumar K
    PLoS Med; 2018 Mar; 15(3):e1002542. PubMed ID: 29590099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome.
    Romanowski MD; Parolin MB; Freitas AC; Piazza MJ; Basso J; Urbanetz AA
    Arq Gastroenterol; 2015; 52(2):117-23. PubMed ID: 26039829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Interlink Between Metabolic-Associated Fatty Liver Disease and Polycystic Ovary Syndrome.
    Vidal-Cevallos P; Mijangos-Trejo A; Uribe M; Tapia NC
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):533-545. PubMed ID: 37495343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
    Chen Y; Wang XJ; Jin HL; Jin L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome.
    Liu D; Gao X; Pan XF; Zhou T; Zhu C; Li F; Fan JG; Targher G; Zhao J
    BMC Med; 2023 Feb; 21(1):62. PubMed ID: 36800955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
    Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
    Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
    Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.
    Jones H; Sprung VS; Pugh CJ; Daousi C; Irwin A; Aziz N; Adams VL; Thomas EL; Bell JD; Kemp GJ; Cuthbertson DJ
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3709-16. PubMed ID: 22837189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome.
    Falzarano C; Lofton T; Osei-Ntansah A; Oliver T; Southward T; Stewart S; Andrisse S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):258-272. PubMed ID: 34491336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
    Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
    World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
    Rocha ALL; Faria LC; Guimarães TCM; Moreira GV; Cândido AL; Couto CA; Reis FM
    J Endocrinol Invest; 2017 Dec; 40(12):1279-1288. PubMed ID: 28612285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Brzozowska MM; Ostapowicz G; Weltman MD
    J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women.
    Tantanavipas S; Vallibhakara O; Sobhonslidsuk A; Phongkitkarun S; Vallibhakara SA; Promson K; Sophonsritsuk A
    Biomed Res Int; 2019; 2019():9047324. PubMed ID: 31467918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome.
    Chakraborty S; Ganie MA; Masoodi I; Jana M; ; Gupta N; Sofi NY
    Indian J Med Res; 2020 Apr; 151(4):333-341. PubMed ID: 32461397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of hepatic steatosis in women with polycystic ovary syndrome.
    Karoli R; Fatima J; Chandra A; Gupta U; Islam FU; Singh G
    J Hum Reprod Sci; 2013 Jan; 6(1):9-14. PubMed ID: 23869143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Kelley CE; Brown AJ; Diehl AM; Setji TL
    World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study].
    Zheng RH; Ding CF
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):98-101. PubMed ID: 18683746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.